Eli Lilly and Company (NYSE:LLY) major shareholder Lilly Endowment Inc sold 200,000 shares of the firm’s stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total value of $17,640,000.00. Following the completion of the sale, the insider now owns 123,084,104 shares of the company’s stock, valued at $10,856,017,972.80. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Lilly Endowment Inc also recently made the following trade(s):

  • On Wednesday, October 4th, Lilly Endowment Inc sold 205,000 shares of Eli Lilly and stock. The shares were sold at an average price of $86.81, for a total value of $17,796,050.00.
  • On Friday, September 29th, Lilly Endowment Inc sold 195,000 shares of Eli Lilly and stock. The shares were sold at an average price of $85.14, for a total value of $16,602,300.00.
  • On Friday, September 15th, Lilly Endowment Inc sold 190,000 shares of Eli Lilly and stock. The shares were sold at an average price of $82.53, for a total value of $15,680,700.00.

Eli Lilly and Company (NYSE LLY) traded up $1.18 during mid-day trading on Thursday, reaching $87.89. The company’s stock had a trading volume of 5,786,800 shares, compared to its average volume of 3,683,472. The firm has a market cap of $95,475.95, a P/E ratio of 21.20, a P/E/G ratio of 1.77 and a beta of 0.35. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. Eli Lilly and Company has a fifty-two week low of $67.54 and a fifty-two week high of $89.09.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The business had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. During the same quarter in the previous year, the business earned $0.88 EPS. The company’s quarterly revenue was up 9.0% on a year-over-year basis. equities research analysts expect that Eli Lilly and Company will post 4.21 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be given a dividend of $0.5625 per share. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $2.25 annualized dividend and a dividend yield of 2.56%. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s dividend payout ratio (DPR) is currently 98.58%.

Several institutional investors have recently bought and sold shares of LLY. Acrospire Investment Management LLC lifted its position in shares of Eli Lilly and by 16.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after buying an additional 200 shares in the last quarter. MPS Loria Financial Planners LLC bought a new position in shares of Eli Lilly and during the 2nd quarter worth approximately $128,000. San Francisco Sentry Investment Group CA bought a new position in shares of Eli Lilly and during the 2nd quarter worth approximately $129,000. Willingdon Wealth Management bought a new position in shares of Eli Lilly and during the 3rd quarter worth approximately $138,000. Finally, Wealthcare Advisory Partners LLC bought a new position in shares of Eli Lilly and during the 3rd quarter worth approximately $142,000. 76.42% of the stock is currently owned by hedge funds and other institutional investors.

Several analysts have recently commented on LLY shares. BMO Capital Markets restated a “sell” rating and issued a $73.00 target price on shares of Eli Lilly and in a research note on Wednesday, August 16th. BidaskClub downgraded Eli Lilly and from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. Jefferies Group restated a “buy” rating and issued a $89.00 target price (down from $94.00) on shares of Eli Lilly and in a research note on Thursday, August 24th. Leerink Swann restated a “hold” rating on shares of Eli Lilly and in a research note on Thursday, August 31st. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $103.00 price target on shares of Eli Lilly and in a research note on Thursday, August 31st. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $90.25.

COPYRIGHT VIOLATION WARNING: This article was posted by Daily Political and is the property of of Daily Political. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://www.dailypolitical.com/2017/12/14/insider-selling-eli-lilly-and-company-lly-major-shareholder-sells-200000-shares-of-stock.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Insider Buying and Selling by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.